Rituximab may be an effective therapeutic option in the management of severe necrotizing scleritis associated with AAV. A middle-aged man was diagnosed with necrotizing scleritis associated with ...

They infected Sf9 cell lines — derived from the fall armyworm — with three different baculoviruses: two containing essential genes for AAV particle production (rep and cap), and one containing ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...

To assist researchers in the selection of the optimal AAV vector for their application, we have generated a detailed map of viral delivery to tissues in mice, the most commonly used experimental ...

Adeno-associated virus (AAV) gene therapies hold great promise, but ensuring product quality is critical. One major challenge? The presence of empty capsids, which can reduce therapeutic effectiveness ...

An analysis of data on patients with AAV who underwent TPE found low short-term complication rates but an increased risk of serious infections. “The removal of autoantibodies and immune ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...